450 EAST 29TH STREET, NEW YORK, NY
Reports Second Quarter 2025 Financial and Operational Results
Reg. FD
Shareholder votes
Reports First Quarter 2025 Financial and Operational Results
Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
Annual Report to Security Holders
Material disclosure
Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates, Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize Proprietary Manufacturing Process
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload